Latest Artia Global Partners LP Stock Portfolio
Artia Global Partners LP Performance:
2025 Q3: 11.46%YTD: 33.07%2024: 12.25%
Performance for 2025 Q3 is 11.46%, and YTD is 33.07%, and 2024 is 12.25%.
About Artia Global Partners LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Artia Global Partners LP reported an equity portfolio of $1.3 Billions as of 30 Sep, 2025.
The top stock holdings of Artia Global Partners LP are INSM, , SLNO. The fund has invested 16.7% of it's portfolio in INSMED INC and 9.2% of portfolio in ARGENX SE.
The fund managers got completely rid off SPDR SER TR (BIL), SPRINGWORKS THERAPEUTICS INC (SWTX) and JANUX THERAPEUTICS INC (JANX) stocks. They significantly reduced their stock positions in VERONA PHARMA PLC (VRNA). Artia Global Partners LP opened new stock positions in UNIQURE NV (QURE), ABIVAX SA and IONIS PHARMACEUTICALS INC (IONS). The fund showed a lot of confidence in some stocks as they added substantially to VERTEX PHARMACEUTICALS INC (VRTX), NEWAMSTERDAM PHARMA COMPANY (NAMS) and PROSHARES TR II (AGQ).
The top stock holdings of Artia Global Partners LP are INSM, , SLNO. The fund has invested 16.7% of it's portfolio in INSMED INC and 9.2% of portfolio in ARGENX SE.
The fund managers got completely rid off SPDR SER TR (BIL), SPRINGWORKS THERAPEUTICS INC (SWTX) and JANUX THERAPEUTICS INC (JANX) stocks. They significantly reduced their stock positions in VERONA PHARMA PLC (VRNA). Artia Global Partners LP opened new stock positions in UNIQURE NV (QURE), ABIVAX SA and IONIS PHARMACEUTICALS INC (IONS). The fund showed a lot of confidence in some stocks as they added substantially to VERTEX PHARMACEUTICALS INC (VRTX), NEWAMSTERDAM PHARMA COMPANY (NAMS) and PROSHARES TR II (AGQ).
Artia Global Partners LP Annual Return Estimates Vs S&P 500
Our best estimate is that Artia Global Partners LP made a return of 11.46% in the last quarter. In trailing 12 months, it's portfolio return was 21.28%.
New Buys
| Ticker | $ Bought |
|---|---|
| uniqure nv | 76,912,900 |
| abivax sa | 38,281,900 |
| dianthus therapeutics inc | 8,556,500 |
| ionis pharmaceuticals inc | 7,873,430 |
| nektar therapeutics | 6,600,290 |
| centessa pharmaceuticals plc | 6,464,610 |
| rapport therapeutics inc | 3,837,720 |
| ocular therapeutix inc | 3,298,010 |
New stocks bought by Artia Global Partners LP
Additions
| Ticker | % Inc. |
|---|---|
| vertex pharmaceuticals inc | 2,404 |
| newamsterdam pharma company | 1,326 |
| proshares tr ii | 539 |
| avidity biosciences inc | 536 |
| eyepoint pharmaceuticals inc | 296 |
| alnylam pharmaceuticals inc | 229 |
| ultragenyx pharmaceutical in | 208 |
| trevi therapeutics inc | 204 |
Additions to existing portfolio by Artia Global Partners LP
Reductions
| Ticker | % Reduced |
|---|---|
| verona pharma plc | -25.39 |
Artia Global Partners LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| spdr ser tr | -8,293,000 |
| springworks therapeutics inc | -3,004,070 |
| janux therapeutics inc | -462,000 |
Artia Global Partners LP got rid off the above stocks
Sector Distribution
Artia Global Partners LP has about 76.7% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 76.7 |
| Others | 23.3 |
Market Cap. Distribution
Artia Global Partners LP has about 37% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| LARGE-CAP | 32.6 |
| UNALLOCATED | 24.5 |
| SMALL-CAP | 18.1 |
| MID-CAP | 16.5 |
| MEGA-CAP | 4.4 |
| MICRO-CAP | 3.8 |
Stocks belong to which Index?
About 43% of the stocks held by Artia Global Partners LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 57 |
| RUSSELL 2000 | 27.7 |
| S&P 500 | 15.3 |
Artia Global Partners LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Artia Global Partners LP
Artia Global Partners LP has 49 stocks in it's portfolio. About 63.9% of the portfolio is in top 10 stocks. SLNO proved to be the most loss making stock for the portfolio. INSM was the most profitable stock for Artia Global Partners LP last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABBV | abbvie inc | 0.53 | 29,000 | 6,714,660 | added | 100 | ||
| AGQ | proshares tr ii | 3.92 | 1,074,740 | 49,502,700 | added | 539 | ||
| ALEC | alector inc | 0.03 | 142,058 | 420,492 | new | |||
| ALNY | alnylam pharmaceuticals inc | 2.50 | 69,140 | 31,527,800 | added | 229 | ||
| BBIO | bridgebio pharma inc | 0.17 | 40,800 | 2,119,150 | new | |||
| BIL | spdr ser tr | 0.00 | 0.00 | 0.00 | sold off | -100 | put | |
| BSX | boston scientific corp | 2.84 | 366,400 | 35,771,600 | added | 136 | ||
| CNTA | centessa pharmaceuticals plc | 0.51 | 266,582 | 6,464,610 | new | |||
| DGX | quest diagnostics inc | 2.47 | 163,434 | 31,147,300 | added | 100 | ||
| EYPT | eyepoint pharmaceuticals inc | 1.42 | 1,256,730 | 17,895,900 | added | 296 | ||
| INSM | insmed inc | 16.71 | 1,464,420 | 210,892,000 | added | 94.55 | ||
| IONS | ionis pharmaceuticals inc | 0.62 | 120,352 | 7,873,430 | new | |||
| JANX | janux therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| KALV | kalvista pharmaceuticals inc | 0.08 | 83,110 | 1,012,280 | new | |||
| LIFE | atyr pharma inc | 0.04 | 744,552 | 537,120 | new | |||
| LLY | eli lilly & co | 3.47 | 57,400 | 43,796,200 | added | 86.97 | ||
| MREO | mereo biopharma group plc | 0.16 | 950,722 | 1,958,490 | added | 100 | ||
| MRNA | moderna inc | 0.10 | 47,600 | 1,229,510 | new | |||
| MRUS | merus n v | 4.43 | 593,500 | 55,878,000 | added | 100 | ||
| NAMS | newamsterdam pharma company | 0.88 | 389,676 | 11,082,400 | added | 1,326 | ||